Published in Pharma Law Weekly, September 6th, 2005
The patent relates to certain drug screening methods utilizing the 19AJ receptor, an orphan G protein-coupled receptor, or GPCR, which was discovered by Arena and is active in regulating blood glucose levels in a glucose-dependent manner. The invention set forth in the patent was utilized to identify the orally bioavailable compounds that Ortho-McNeil, Inc., a Johnson & Johnson company, and Arena are developing to treat diabetes as part of the collaboration they initiated in December 2004.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.